| |
Revolutionize your clinical trial! IQVIA experts discuss how the synergy between wearables and eCOA will enhance data collection, patient engagement, regulatory compliance and streamline trial processes. Watch this webinar replay now. .png)
|
|
|
Thursday, July 22, 2025 | 10am ET / 7am PT Join us to take an exciting look at the forefront of REMS transformation. Learn how leading technology, integrated strategies and operational excellence are redefining what’s possible. Gain the insights you need to reduce complexity, enhance compliance and deliver more value across the REMS lifecycle. Register now. 
|
|
| By Gabrielle Masson Sarepta Therapeutics has laid off 500 staffers, or 36% of its workforce, as part of a strategic restructuring aiming to save $400 million annually. |
|
|
|
By James Waldron,Fraiser Kansteiner Although many of the complete response letters uploaded by the FDA this week have been subtly disclosed in drug approval packages over the years, the consolidation of the rejection notices offers an in-depth view into the high-stakes discussions that decide whether a medicine will ever make it to market. |
By Conor Hale For 2025, the to-be-combined company’s portfolios and its 16,000 total employees are expected to generate about $6.5 billion in sales. |
By Andrea Park After a nine-month investigation into direct-to-consumer telehealth platforms launched by Eli Lilly and Pfizer, a group of senators has released a report suggesting the platforms may allow pharmas to inappropriately influence doctors’ prescribing habits. |
By Darren Incorvaia As measles cases surge to record levels in the U.S., Department of Health and Human Services Secretary Robert F. Kennedy Jr. has downplayed the effectiveness of the long-used vaccine and instead promoted the development of new treatments for the virus. |
By Zoey Becker The FDA listed observations at plants run by Sun Pharma, Daewoo Pharmaceutical and Glenmark, citing concerns ranging from mold to quality control issues. |
By Fraiser Kansteiner With GSK kicking its R&D engine into high gear in recent years, a shuffling of the scientific priorities at the company is only natural. But for a small subset of staffers, that redistribution of resources will mean job cuts, even as GSK eyes major R&D investments on the horizon. |
By Angus Liu The manufacturing-related rejection for UX111 is more than a setback for Ultragenyx, as it also delays a key test of the new FDA leadership’s much-touted support for cell and gene therapies against rare diseases. |
By Gabrielle Masson International companies are increasingly inking licensing deals with Chinese biotechs as concerns regarding drug pricing and patent expirations continue to rise. |
By Eric Sagonowsky As GSK's Blenrep makes its return to markets around the world, the company has big expectations for the antibody-drug conjugate. But FDA reviewers are taking a close look at safety data from two phase 3 trials. |
By Andrea Park In an echo of the pattern laid last year, following a record-high outlay at the very beginning of the year, TV drug ad spending has crept downward as 2025 has gone on. |
Fierce podcasts Don’t miss an episode |
| In this episode of "Podnosis," we explore how Walmart heir Alice Walton’s new medical school in Arkansas is rethinking medical education with a whole health approach that values empathy, the arts and business alongside clinical training. |
|
|---|
|
|
|
Wednesday, July 30, 2025 | 2pm ET / 11am ET Attend this webinar to learn how life sciences organizations can tap into a connected ecosystem to advance research, clinical strategy, supply chain transparency and commercial effectiveness. Register Today. 
|
|
Whitepaper This white paper outlines how we apply industry-backed practices and proprietary technologies to proactively safeguard sterility and performance. Sponsored by: Lonza |
Whitepaper Presented by Blue Matter, strategic consultants in the life sciences Sponsored by Blue Matter Consulting |
Whitepaper Learn how to transform your Patient Support Programs into measurable patient-centric initiatives that inform strategic decision making. Sponsored by Herspiegel Consulting |
Executive Summary Biotech innovation doesn’t slow down—and neither should your lab partner. This brief outlines how early scientific engagement, operational transparency, and integrated global lab services help reduce risk, stay on schedule, and deliver results. Whether you're navigating your first trial or scaling a growing pipeline, see how a purpose-built lab model can help you move smarter and faster. Sponsored by: IQVIA Laboratories |
Whitepaper Learn how clinical terminology helps life sciences teams streamline cohorting, reduce bias, and accelerate evidence generation. Sponsored by: IMO Health |
| Sheraton Philadelphia Downtown |
|
| The Lighthouse at Pier 61 in New York City |
|
|
| |
|
